Cellular pathways that repair chromosomal double-strand breaks (DSBs) have pivotal roles
in cell growth, development and cancer. These DSB repair pathways have been the target of …

Resistance to chemo-and radiotherapy is a common event among cancer patients and a
reason why new cancer therapies and therapeutic strategies need to be in continuous …

Recently developed inhibitors of polymerase theta (POLθ) have demonstrated synthetic
lethality in BRCA-deficient tumor models. To examine the contribution of the immune …

DNA repair pathway inhibitors are a new class of anticancer drugs that are advancing in
clinical trials. Peposertib is an inhibitor of DNA-dependent protein kinase (DNA-PK), which is …

Synthetic lethality (SL) is an innovative strategy in targeted anticancer therapy that exploits
tumor genetic vulnerabilities. This topic has come to the forefront in recent years, as …

Background p53 plays a key role in the DNA repair process and response to ionising
radiation. We sought to determine the clinical phenotype of TP53 mutations and p53 …

Leukemia cells accumulate DNA damage, but altered DNA repair mechanisms protect them
from apoptosis. We showed here that formaldehyde generated by serine/1-carbon cycle …

The non-homologous end joining pathway is vital for repairing DNA double-strand breaks
(DSB), with DNA-dependent protein kinase (DNA-PK) playing a critical role. Altered DNA …

Homologous recombination repair (HRR) is the cellular mechanism for error-free repair of
double strand DNA (dsDNA) breaks. Cancer cells with mutations in both alleles of genes …

Genome integrity and genome engineering require efficient repair of DNA double-strand
breaks (DSBs) by non-homologous end joining (NHEJ), homologous recombination (HR), or …